Ontology highlight
ABSTRACT: Background
The adaptation to hypoxia is mainly controlled by the HIF transcription factors. Increased expression/activity of HIF-1α correlates with poor prognosis in cancer patients. PARP-1 inhibitors are used in the clinic to treat BRCAness breast/ovarian cancer and have been shown to regulate the hypoxic response; therefore, their use could be expanded.Methods
In this work by integrating molecular/cell biology approaches, genome-wide ChIP-seq, and patient samples, we elucidate the extent to which PARP-1 exerts control over HIF-1-regulated genes.Results
In human melanoma, PARP-1 and HIF-1α expression are strongly associated. In response to a hypoxic challenge poly(ADP-ribose) (PAR) is synthesized, HIF-1α is post-transcriptionally modified (PTM) and stabilized by PARylation at specific K/R residues located at its C-terminus. Using an unbiased ChIP-seq approach we demonstrate that PARP-1 dictates hypoxia-dependent HIF-recruitment to chromatin in a range of HIF-regulated genes while analysis of HIF-binding motifs (RCGTG) reveals a restriction on the recognition of hypoxia responsive elements in the absence of PARP-1. Consequently, the cells are poorly adapted to hypoxia, showing a reduced fitness during hypoxic induction.Conclusions
These data characterize the fine-tuning regulation by PARP-1/PARylation of HIF activation and suggest that PARP inhibitors might have therapeutic potential against cancer types displaying HIF-1α over-activation.
SUBMITTER: Marti JM
PROVIDER: S-EPMC7878192 | biostudies-literature | 2021 May
REPOSITORIES: biostudies-literature
Martí Juan Manuel JM Garcia-Diaz Angel A Delgado-Bellido Daniel D O'Valle Francisco F González-Flores Ariannys A Carlevaris Onintza O Rodríguez-Vargas José Manuel JM Amé Jean Christophe JC Dantzer Françoise F King George L GL Dziedzic Klaudia K Berra Edurne E de Álava E E Amaral A T AT Hammond Ester M EM Oliver F Javier FJ
Redox biology 20210201
<h4>Background</h4>The adaptation to hypoxia is mainly controlled by the HIF transcription factors. Increased expression/activity of HIF-1α correlates with poor prognosis in cancer patients. PARP-1 inhibitors are used in the clinic to treat BRCAness breast/ovarian cancer and have been shown to regulate the hypoxic response; therefore, their use could be expanded.<h4>Methods</h4>In this work by integrating molecular/cell biology approaches, genome-wide ChIP-seq, and patient samples, we elucidate ...[more]